**CIHR-INMD-CASL Early Career Researcher Partnership Prize**

**NOMINATION FORM**

**Objectives**

The CIHR-INMD-CASL Early Career Researcher Partnership Prize (“the Partnership Prize”) is designed to recognize exceptional young investigators with an interest specifically in some aspect of liver disease, and who are a member of the Canadian Association for the Study of the Liver.

**Criteria**

The Prize will recognize one (1) regular CASL member who meets the following criteria:

* is an early career researcher (ECR) as [defined](https://cihr-irsc.gc.ca/e/34190.html#r14) by the CIHR – i.e., someone who is less than five years from the date of their first research appointment (calculations of eligibility may be adjusted for part-time appointments and leaves of absence);
* is a Canadian citizen or permanent resident;
* holds an academic appointment in a Canadian university or affiliated institution; and
* has a primary research interest in liver disease (including clinical investigators or basic scientists)

**Recipient Recognition**

In addition to a Certificate of Recognition, the successful recipient receives a prize of $2,500 CDN.

Recipients will be recognized as part of the annual CASL Awards Ceremony, which takes place in conjunction with the Canadian Liver Meeting.

**Nomination Requirements and Process**You may submit a nomination for yourself or may nominate another individual for the prize. Nomination packages should include:

* the completed application form;
* a copy of the nominee's CV (CIHR Biosketch Common CV format is preferred);
* a one-page (min. 10-point font) description of the nominee's research program and its potential to advance research or benefit the care of patients with liver disease in Canada; and
* one (1) letter of support from an individual such as the nominee's department head, supervisor, mentor, or another individual who can comment on the nominee’s research program and potential (2 pages max.)

**Instructions**

1. Use the application form (pages 2-3) as a cover page. Answer **all** questions by print or type.
2. Include additional documents and provide signatures as requested.
3. Do not use fonts smaller than 10-point type. Items may be single-spaced, but please make the presentation as user-friendly to the reviewers as possible.
4. Assemble the nomination package into a single PDF, in the order listed above. Clearly label each piece of additional information. Complete all sections.
5. Referees may email their letter directly to the CASL office at [casl@hepatology.ca](mailto:casl@hepatology.ca) using “Reference Letter for [Nominee Name]’s ECR Partnership Prize Nomination” as the subject line.
6. Please adhere to the stated page limits.
7. Email your nomination package to [casl@hepatology.ca](mailto:casl@hepatology.ca) on or before September 15, 2021.

**CIHR-INMD-CASL Early Career Researcher Partnership Prize Nomination Form**

**Nominee Information**

**Membership/Citizenship Status**Nominees must be regular CASL members in good standing, and a Canadian citizen or Permanent Resident. By checking the boxes below, you are acknowledging that you meet these requirements.

* Nominee is a CASL member
* Nominee is a Canadian Citizen or Permanent Resident

**Nominee Information**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Prefix, First and Last Name

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Email Address

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Degree(s) and Year(s) granted

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Current Position Appointment Date (month/year)

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Institution Name

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Institution Address

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  
City, Province, Postal Code

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Office Telephone

**Supervisor/Mentor Information**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Supervisor Prefix, First and Last Name

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Supervisor’s Title

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Supervisor’s Office Telephone Email Address

**Required Documents**

* ***CV (CIHR Biosketch Common CV preferred)*** – Ensure that your CV includes recent awards, publications and presentations.
* ***Research Description*** – Description of the nominee's research program and its potential to advance research or benefit the care of patients with liver disease in Canada (1 page).

***The following may be submitted as part of the application package, or emailed directly to the CASL office at*** [***casl@hepatology.ca***](mailto:casl@hepatology.ca)***:***

* ***Letter of Reference*** – Letter from an individual such as the Department or Program Chair, past or current supervisor, mentor, or another individual who can speak to the nominee’s research program and potential (max. 2 pages).

**Signature**

Note: Your signature below indicates that the nominee meets the eligibility criteria for this prize and that the information in this application is accurate to the best of your knowledge.

Signature Name Date

Email your completed application and all documents to [casl@hepatology.ca](mailto:casl@hepatology.ca) by **September 15, 2021.**